Patents Issued in May 15, 2008
-
Publication number: 20080113329Abstract: A computer-implemented method, system, and computer program product for implementing a lessons learned knowledge management system is provided. The computer-implemented method includes building a project database which, in turn, includes identifying project phases for a project, identifying categories for the project, and mapping each of the categories to respective phases of the project. The computer-implemented method further includes generating a workflow structure for the project, which includes assigning a reviewer to each of the categories, assigning an action owner to each of the categories, the action owner tasked with taking action on the lesson learned and defining a routing plan and timeline for transmittal of the lesson learned between the reviewer and the action owner. The computer-implemented method also includes processing lessons learned received for the project via the project database and the workflow structure.Type: ApplicationFiled: November 13, 2006Publication date: May 15, 2008Applicant: INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: Lara Cumberland, Athena Taylor, Douglas E. Ziemke
-
Publication number: 20080113330Abstract: The present invention is directed towards educating adolescent parents and their young children. The education methodology includes one curricular component that is directed specifically toward educating adolescent parents, one curricular component that is directed specifically toward educating young children of adolescent parents. The education methodology may also include a curricular component that is directed toward educating adolescent parents about parenting and life skills. The education methodology may also include a curricular component that is directed toward fostering parent and child interaction and teaching by adolescent parents to their young children. Finally, the education methodology may be at least partially implemented residential facility that allows adolescent parents and their young children to live together.Type: ApplicationFiled: November 13, 2007Publication date: May 15, 2008Inventor: Aminyah Muhammad-M'Backe
-
Publication number: 20080113331Abstract: A system, device, and method for mixing a substance with a liquid pumps the liquid into a container of the substance to produce a solution. The container may be part of a container assembly including a port assembly for coupling with the container to produce an inlet and/or and outlet port for the container. The container assembly may be received within a receiving chamber for causing the coupling. The solution may be permitted to flow out of the outlet port when the solution rises within the container to a level of the outlet port so that the substance is partially diluted before flowing out of the outlet port.Type: ApplicationFiled: October 29, 2007Publication date: May 15, 2008Applicant: DEKA Products Limited PartnershipInventors: Jason D. Demers, James D. Dale, Brian Tracey, David W. McGill, Larry B. Gray
-
Publication number: 20080113332Abstract: The invention relates to a method of using density maps based on marker values, and in particular tumour markers and other indicator substances/values for the diagnosis of patients with diseases, in particular tumourous diseases, and especially prostate carcinoma.Type: ApplicationFiled: June 1, 2005Publication date: May 15, 2008Inventors: Thomas Keller, Hermann Butz
-
Publication number: 20080113333Abstract: A method for the prevention of the adhesion of particles, in particular cells and cellular components in solution to surfaces, characterized in that to the solution is added at least one polyalcohol.Type: ApplicationFiled: September 13, 2007Publication date: May 15, 2008Applicant: EVOTEC OAI AGInventor: Gabriele Gradl
-
Publication number: 20080113334Abstract: The present invention provides a method for performing a biological test under conditions in which an artificially prepared cell pattern with initial position coordinates that can be determined is three-dimensionally cultured within a gelled matrix. The present invention relates to a biological test method that comprises testing a biological indicator with reference to at least one selected from the group consisting of cell proliferation, cell movement, and cell differentiation in a cell pattern substantially embedded in gel. The present invention also relates to a kit for the biological test method.Type: ApplicationFiled: November 8, 2007Publication date: May 15, 2008Applicant: Dai Nippon Printing Co., Ltd.Inventors: Hideshi HATTORI, Norihiko Okochi, Masatoshi Kuroda, Masahiko Hase
-
Publication number: 20080113335Abstract: The present invention refers to HIV-based recombinant viral clones that possess the general structure represented in FIG. 8 and are the result of the following genetic manipulations: deletion of HIV fragments (for example, Nef gene) without losing infective capacity, insertion of a non-expressed gene in human cells, insertion of LacZ gene, introduction of restriction sites for extracting DNA fragments of matrix provirus and substituting them for genes from patients to assess. The present invention also refers to the application of these clones in analytical methods related to AIDS.Type: ApplicationFiled: May 10, 2005Publication date: May 15, 2008Inventors: Jose Alcami Pertejo, Javier Garcia Perez, Sonsoles Sanchez Palomino, Nuria Gonzalez Fernandez
-
Publication number: 20080113336Abstract: In accordance with the present invention, there is provided a new method for detection and quantification of virus and viral particles, comprising the step of labeling the nucleic acids of an intact virus or viral particle with a dye that emits fluorescence once complexed with the nucleic acids and detecting the virus or viral particle with a chromatograph equipped with a fluorescence detector.Type: ApplicationFiled: November 18, 2005Publication date: May 15, 2008Inventors: Julia Transfiguracion, Amine Kamen
-
Publication number: 20080113337Abstract: The present invention provides a method and device of quantitatively or qualitatively examining and judging the presence of virus infection, such as HIV, or the presence of prion infection by: irradiating a sample derived from an examinee or other animal with light having a wavelength in a range of 400 nm to 2500 nm or a wavelength in part of the range; detecting reflected light, transmitted light, or transmitted and reflected light to obtain an absorption spectral data; and analyzing the absorbance at all measurement wavelengths or at specific wavelengths in the absorption spectral data by using an analytical model prepared beforehand. The analytical model can be prepared by carrying out spectral measurement, with a perturbation being provided, and carrying out a multivariate analysis that brings out perturbation effects.Type: ApplicationFiled: November 10, 2005Publication date: May 15, 2008Applicants: THE NEW INDUSTRY RESEARCH ORGANIZATION, OSAKA UNIVERSITYInventors: Akikazu Sakudo, Roumiana Tsenkova, Kazuyoshi Ikuta, Takashi Onodera
-
Publication number: 20080113338Abstract: The present specification discloses methods of determining risk of developing Dengue Hemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS) in an individual infected with dengue virus (DV). The methods comprise determining, in a fluid or tissue sample of an individual, the presence, absence or quantity of dengue virus protein NS1, and determining, in a fluid or tissue sample of the individual, presence, absence or quantity of SC5b-9 complement complex. The methods can further comprise comparing the levels of NS1 protein and SC5b-9 complement complex with a database comprising epidemiological data correlating levels of NS1 protein and SC5b-9 complement complex with probability of developing DHF/DSS in a population.Type: ApplicationFiled: June 15, 2007Publication date: May 15, 2008Inventors: Panisadee Avirutnan, Prida Malasit, Sucharit Bhakdi Punyaratabhandu, Watchara Kasinrerk, Chunya Puttikhunt
-
Publication number: 20080113339Abstract: An in vitro method that allows detection of hepatitis C by detecting hepatitis C virus (HCV) core protein and antibodies to HCV core protein (anti-core antibodies) in a single assay is provided. Cross-reactivity is eliminated in the method preferably by utilizing short peptides, each of which has an amino acid sequence that corresponds to an immunodominant region of the native core protein but which does not wholly encompass the epitope bound by the antibodies utilized in the method. The method can be used to detect the presence of HCV in a subject, and/or to determine the suitability of donor blood or blood products for transfusion purposes. Also provided are diagnostic kits for carrying out the method and a process for selecting suitable capture peptides and monoclonal antibodies for use in the combination method.Type: ApplicationFiled: August 28, 2007Publication date: May 15, 2008Inventors: Brian C. Rodgers, Graham J. Burch
-
Publication number: 20080113340Abstract: In certain aspects, the invention relates to methods of diagnosing cervical cancer by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length. In other aspects, the invention relates to methods of detecting immortalization of cervical cells by using a combination of certain biomarkers. In yet other aspects, the invention relates to methods of classifying the grade of a cervical lesion for diagnostic and prognostic purposes in a female. In further aspects, the invention relates to methods of treating cervical cancer by administering a therapeutic agent that targets one or more of these biomarkers.Type: ApplicationFiled: January 11, 2008Publication date: May 15, 2008Applicant: Georgetown UniversityInventor: Richard Schlegel
-
Publication number: 20080113341Abstract: The invention provides novel fluorinated resorufin compounds that are of use in a variety of assay formats. Also provided are methods of using the compounds and kits that include a compound of the invention and instructions detailing the use of the compound in one or more assay formats.Type: ApplicationFiled: January 16, 2008Publication date: May 15, 2008Applicant: INVITROGEN CORPORATIONInventors: Robert BATCHELOR, Yue GE, Iain JOHNSON, Wai-Yee LEUNG, Jixiang LIU, Brian PATCH, Peter SMALLEY, Thomas STEINBERG
-
Publication number: 20080113342Abstract: The present invention is in the field of plant biochemistry and genetics. More specifically the invention relates to nucleic acid sequences from plant cells, in particular, genomic DNA sequences from Arabidopsis thaliana plants. The invention encompasses nucleic acid molecules present in non-coding regions as well as nucleic acid molecules that encode proteins and fragments of proteins. In addition, the invention also encompasses proteins and fragments of proteins so encoded and antibodies capable of binding these proteins or fragments. The invention also relates to methods of using the nucleic acid molecules, proteins and fragments of proteins, and antibodies, for example for genome mapping, gene identification and analysis, plant breeding, preparation of constructs for use in plant gene expression, and transgenic plants.Type: ApplicationFiled: February 16, 2000Publication date: May 15, 2008Applicant: Monsanto Technology LLCInventors: Yongwei CAO, William TIMBERLAKE
-
Publication number: 20080113343Abstract: The present invention relates to a method of inhibiting or reducing the proliferation of prostate cancer cells, such as androgen independent prostate cancer (AIPC) cells, the method comprising administering to the cells a PLA2 inhibitor. In one embodiment the PLA2 inhibitor is a conformationally constrained molecule derived from a peptide consisting essentially of amino acid residues 70-74 of a human sPLA2-IIA protein, or the equivalent residues in other sPLA2 proteins.Type: ApplicationFiled: June 10, 2003Publication date: May 15, 2008Inventors: Garry George Graham, Qihan Dong
-
Publication number: 20080113344Abstract: The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and breast cancer in particular. Genes that are differentially expressed in breast tissue of breast cancer patients versus those of normal people are disclosed.Type: ApplicationFiled: October 15, 2004Publication date: May 15, 2008Inventors: Ralph Wirtz, Marc Munnes
-
Publication number: 20080113345Abstract: Gene signatures, specific marker genes, and diagnostic assays for predicting progression free survival and objective response to anti-estrogen, e. g., tamoxifen therapy for recurring breast cancer patients are described.Type: ApplicationFiled: December 3, 2004Publication date: May 15, 2008Applicant: Erasmus MCInventors: Petronella M.J.J. Berns, Maurice P.H.M. Jansen, John A. Foekens, Johannes G.M. Klijn
-
Publication number: 20080113346Abstract: It is intended to identify rheumatoid arthritis susceptibility genes by a highly efficient, low-cost mapping method using microsatellites. In the present invention, novel rheumatoid arthritis susceptibility genes, that is, TNXB, NOTCH4, RAB6A, MPRL48, UCP2, and UCP3 genes, in the human genomic DNA sequence were identified by conducting case-control association analysis on rheumatoid arthritis by use of microsatellite polymorphic markers assigned at approximately 100-kb intervals to narrow down candidate regions and then conducting association analysis and linkage analysis with SNP as a marker.Type: ApplicationFiled: March 29, 2005Publication date: May 15, 2008Inventors: Hidetoshi Inoko, Gen Tamiya, Takashi Gojobori
-
Publication number: 20080113347Abstract: The present invention refers to an in vitro method for detecting the presence of demyelinating diseases in an individual, for determining the stage or severity of said diseases in the individual, or for monitoring the effect of the therapy administered to an individual suffering said diseases; to the search, identification, development and evaluation of efficacy of compounds for therapy of said diseases for the purpose of developing new drugs; as well as to agents inhibiting DUSP6 protein expression and/or activity, and/or the effects of this expression. The methods and agents of the invention are preferably applied to multiple sclerosis.Type: ApplicationFiled: December 28, 2004Publication date: May 15, 2008Inventors: Ainara Vallejo Illarramendi, Antonio Martinez Martinez, Usue Ariz Lopez de Castro, Lourdes Osaba Ortiz de Mendibil, Corina Junquera Sanchez-Vallejo, Simon Santa Cruz, Pedro Escudero Garcia de Galdeano, Jorge Ochoa Garay, Laureano Simon Buela, Carlos Matute Almau, Elena Alberdi Alfonso, Maria Victoria Sanchez Gomez, Gaskon Ibarretxe Bilbao, Estibaliz Etxebarria Galnares
-
Publication number: 20080113348Abstract: The present invention relates to a method for cleaning and isolating nucleic acids using cationic detergents with the general formula (I): Y+R1R2R3R4X? ??(I) where Y can represent nitrogen or phosphorus R1, R2, R3 and R4 can represent independently from one another an unbranched or branched C1-C20-alkyl residue, C3-C6-alkenyl residue, C3-C6-alkinyl residue and/or a C6-C20-aryl residue as well as a C6-C26-aralkyl residue, and X— can represent an anion of an inorganic or organic single or multi-basic acid.Type: ApplicationFiled: July 15, 2005Publication date: May 15, 2008Inventor: Thorsten Singer
-
Publication number: 20080113349Abstract: The present invention relates to a PCR (polymerase chain reaction) based assay that is useful for detecting, identifying, quantitating and analysis of a target nucleic acid (target nucleic acid hereinafter) in a sample. More specifically, the present invention relates to a PCR based assay that can improve accuracy in detecting, identifying, and quantitating contamination in mammalian cell lines using a PCR-based assay of nucleic acid oligonucleotides (oligoprobes) having a sequence expected to be complementary to a target nucleic acid sequence in a sample. More specifically, the sample may contain either cells or nucleic acid isolated from a cell line. The present invention also relates to a detection kit using the PCR-based assay.Type: ApplicationFiled: November 3, 2006Publication date: May 15, 2008Inventors: Pranvera Ikonomi, Jason Cooper, Greg Sykes, Yvonne Reid
-
Publication number: 20080113350Abstract: Amplification and overexpression of theHER-2 oncogene in breast cancer is felt to be stable over the course of disease and concordant between the primary tumor and metastases. Therefore, patients with HER-2 negative primary tumors will rarely receive anti-HER-2 antibody therapy. A very sensitive blood test is used to capture circulating tumor cells (CTC's) and evaluate their HER-2 gene status by FISH evaluation. The HER-2 status of the primary tumor and corresponding CTC's is used to assess the ratio of CTC's as a reliable surrogate marker. HER-2 expression of 10 CTC's is sufficient to make a definitive diagnosis of the HER-2 gene status for the whole population of CTC's in patients with recurrent breast cancer.Type: ApplicationFiled: November 9, 2006Publication date: May 15, 2008Inventor: Leon W.M.M. Terstappen
-
Publication number: 20080113351Abstract: The present invention provides a polynucleotide that not only has a high RNA interference effect on its target gene, but also has a very small risk of causing RNA interference against a gene unrelated to the target gene. A sequence segment conforming to the following rules (a) to (d) is searched from the base sequences of a target gene for RNA interference and, based on the search results, a polynucleotide capable of causing RNAi is designed, synthesized, etc.: (a) The 3? end base is adenine, thymine, or uracil, (b) The 5? end base is guanine or cytosine, (c) A 7-base sequence from the 3? end is rich in one or more types of bases selected from the group consisting of adenine, thymine, and uracil, and (d) The number of bases is within a range that allows RNA interference to occur without causing cytotoxicity.Type: ApplicationFiled: November 13, 2006Publication date: May 15, 2008Applicant: alphaGEN Co., Ltd.Inventors: Yuki Naito, Masato Fujino, Shinobu Oguchi, Yukikazu Natori
-
Publication number: 20080113352Abstract: Described is a method for electrochemically patterning a microelectrode array (MEA) with at least two different kinds of macromolecules. Said method comprising the steps of: providing a platform with a surface that comprises individually addressable conductive microelectrode surfaces; covering said platform surface with an adlayer of resistant polymer; desorbing said adlayer from a first kind of conductive microelectrodes intended for the selective adsorption of a first kind of macromolecules, in particular proteins, by applying a potential; subjecting the desorbed surfaces to the first macromolecule under conditions such that said first macromolecule adsorbs to said desorbed surfaces, and repeating the desorption/adsorption steps with a second or further kind of macromolecules until all kinds of desired macromolecules are adsorbed. A microchip array produced by the inventive method is also described. Such chip arrays can be used to study a large diversity of biological interactions, e.g.Type: ApplicationFiled: September 20, 2005Publication date: May 15, 2008Inventors: Janos Voros, Marcus Textor, Clarence Tang, Beat Keller
-
Publication number: 20080113353Abstract: The present patent application describes a cantilever for atomic force microscopy (AFM), which includes a cantilever body having a fixed end and a free end, the free end having a surface region being chemically modified by a dendron in which a plurality of termini of the branched region of the dendron are bound to the surface, and a terminus of the linear region of the dendron is functionalized.Type: ApplicationFiled: February 12, 2007Publication date: May 15, 2008Applicants: POSTECH Foundation, POSCOInventors: Joon-Won Park, Yu Jin Jung, Bong Jin Hong, Saul J.R. Tendler, Stephanie Allen
-
Publication number: 20080113354Abstract: Methods and kits are provided with DNA substrates having a fluorescent label positioned at a nucleotide internal from its 5? end for use with CEL nuclease to determine whether a DNA sequence contains mutations or polymorphic changes.Type: ApplicationFiled: November 14, 2005Publication date: May 15, 2008Inventors: Yanggu Shi, Gary F. Gerard
-
Publication number: 20080113355Abstract: The invention provides improved methods for detecting the presence of expanded CGG repeats in the fragile X mental retardation 1 (FMR1) gene and for quantifying the amount of protein produced by the gene.Type: ApplicationFiled: July 18, 2007Publication date: May 15, 2008Applicant: Regents of the University of CaliforniaInventors: Paul J. Hagerman, Flora Tassone, Christine K. Iwahashi
-
Publication number: 20080113356Abstract: A method for separating and purifying a nucleic acid comprising steps of: (1) adding a lysis solution to a biomaterial to prepare a sample solution containing a nucleic acid, and adding a water-soluble organic solvent or a solution containing a water-soluble organic solvent to the sample solution thereby preparing a sample solution containing the water-soluble organic solvent; (2) contacting the sample solution containing the water-soluble organic solvent with a solid phase thereby adsorbing the nucleic acid on the solid phase; (3) contacting a washing solution with the solid phase thereby washing the solid phase in a state where the nucleic acid is adsorbed on the solid phase; and (4) contacting a recovering solution with the solid phase thereby desorbing the nucleic acid from the solid phase, wherein, in the step (1), the water-soluble organic solvent or the solution containing the water-soluble organic solvent is added separately in at least two batches.Type: ApplicationFiled: February 2, 2006Publication date: May 15, 2008Applicant: FUJIFILM CORPORATIONInventors: Tasuku Sasaki, Hiroko Inomata, Rie Iwata
-
Publication number: 20080113357Abstract: The invention relates to methods of isolating nucleic acids from a sample using a filter device comprising a plurality of membranes. The invention also provides for devices comprising a plurality of membranes and kits suitable for isolating nucleic acids from a sample. The invention also provides for nucleic acids which bind to at least a portion of a microorganism genome and methods of using the same.Type: ApplicationFiled: June 4, 2007Publication date: May 15, 2008Applicant: Millipore CorporationInventors: Ricky Francis Baggio, George A. Gagne, Manjula Aysola, Julie R. Murrell
-
Publication number: 20080113358Abstract: The present invention provides systems, apparatuses, and methods to isolate, select or detect the presence of a target cell (e.g., fetal cells) in a sample comprising mixed populations of cells that vastly outnumber the target cells. Target cells include fetal cells, such as nucleated red blood cells, and methods of selecting such cells include diagnosis of fetal abnormalities, i.e., aneuploidy. Furthermore, methods comprise utilizing fetal biomarkers to select fetal cells in a sample comprising fetal and adult cells.Type: ApplicationFiled: July 30, 2007Publication date: May 15, 2008Inventors: Ravi Kapur, Mehmet Toner, Zihua Wang
-
Publication number: 20080113359Abstract: An arsenic ion active DNAzyme includes a nucleotide sequence, which has a base sequence selected from ATCTCCTCCTGTTC (SEQ ID NO: 62), ATCTGCTCCTGTTC (SEQ ID NO: 63), ATCTCCTCATGTTC (SEQ ID NO: 64), ATCTCCTCTTGTTC (SEQ ID NO: 65), ATCTCCAACCTGTTC (SEQ ID NO: 66), and CCGTAGCGCAAAT (SEQ ID NO: 67). A mercury ion active DNAzyme includes a nucleotide sequence, which has a base sequence selected from AATTCCGTAGGTCCAGTG (SEQ ID NO: 68), AATTCCGTCGGTCCAGTG (SEQ ID NO: 69), AATTCCGCCGGTCCAGTG (SEQ ID NO: 70), GGTTCCGAGTCTCGCGTG (SEQ ID NO: 71), and CGTTCAAAAGGGGCACTG (SEQ ID NO: 72). Sensors incorporating the respective DNAzymes are also disclosed.Type: ApplicationFiled: August 29, 2007Publication date: May 15, 2008Inventors: Peter Adriaens, Raveender Vannela
-
Publication number: 20080113360Abstract: Methods and compositions for evaluating gene expression in melanoma samples are provided herein.Type: ApplicationFiled: September 7, 2007Publication date: May 15, 2008Inventors: Adam I. Riker, Steven Alan Enkemann
-
Publication number: 20080113361Abstract: A system is provided that can include: a plurality of retainment regions, where each retainment region is adapted to retain a respective type of an oligonucleotide supported on a respective support; a mixture retainment region; a handling device; a control unit adapted to control the handling device; and a separating unit adapted to simultaneously separate different supported oligonucleotides from their respective supports. A method is provided that can include: pooling together a plurality of supported oligonucleotides to form a mixture; and simultaneously separating the oligonucleotides of the supported oligonucleotides in the mixture from their supports.Type: ApplicationFiled: October 2, 2007Publication date: May 15, 2008Applicant: Applera CorporationInventor: Charles S. Vann
-
Publication number: 20080113362Abstract: Cellular mRNA-protein (mRNP) complexes are partitioned in vivo by contacting a biological sample with at least one ligand that specifically binds at least one component of a mRNP complex. Suitable biological samples comprise at least one mRNA-protein (mRNP) complex and include cell cultures, cell extracts, and whole tissue, including tumor tissue. Ligands include antibodies that specifically bind RNA-binding or RNA-associated proteins present in the mRNP complex. The mRNP complex is separated by binding the ligand with a binding molecule specific for the ligand, where the binding molecule is attached to a solid support. The mRNP complex is collected by removing the mRNP complex from the solid support. After collecting the mRNP complex, the mRNA bound within the complex may be characterized and identified. Subsets of the total mRNA population of a cell may accordingly be characterized, and a gene expression profile of the cell obtained.Type: ApplicationFiled: October 30, 2007Publication date: May 15, 2008Applicant: RIBONOMICS, INC.Inventors: Jack D. Keene, Scott A. Tennenbaum, Craig C. Carson
-
Publication number: 20080113363Abstract: A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 70 to 72 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.Type: ApplicationFiled: November 6, 2007Publication date: May 15, 2008Applicant: CANON KABUSHIKI KAISHAInventors: Toshifumi Fukui, Hiroto Yoshii, Hideto Kuribayashi
-
Publication number: 20080113364Abstract: A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 84 to 86 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.Type: ApplicationFiled: November 6, 2007Publication date: May 15, 2008Applicant: CANON KABUSHIKI KAISHAInventors: Toshifumi Fukui, Hiroto Yoshii, Hideto Kuribayashi
-
Publication number: 20080113365Abstract: A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 76 to 77 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.Type: ApplicationFiled: November 6, 2007Publication date: May 15, 2008Applicant: CANON KABUSHIKI KAISHAInventors: Hideto Kuribayashi, Toshifumi Fukui, Hiroto Yoshii
-
Publication number: 20080113366Abstract: A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 68 to 69 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.Type: ApplicationFiled: November 6, 2007Publication date: May 15, 2008Applicant: CANON KABUSHIKI KAISHAInventors: Hideto Kuribayashi, Toshifumi Fukui, Hiroto Yoshii
-
Publication number: 20080113367Abstract: Apparatus, methods, and systems for useful sampling of seed, wherein viability is maintained, are disclosed. Seed from one generation in a plant advancement experiment is individually sampled by removal and collection of tissue from the seed using a hand-held and manually operated tool having one or more cutting edges. The tissue is then processed to derive one or more biochemical, genetic, or phenotypic characteristic of the seed before a decision is made whether to utilize that seed further in a plant advancement experiment or other plant research and development. In some embodiments of the method, the sampling is controlled to remove a useful amount of tissue for analytical purposes without significant effect on viability potential of the sampled seed. In some embodiments, the sampling is controlled to deter contamination of the sample. In some embodiments, the seed is held in pre-determined orientation to facilitate efficient and accurate sampling.Type: ApplicationFiled: November 13, 2007Publication date: May 15, 2008Applicant: PIONEER HI-BRED INTERNATIONAL, INC.Inventors: STEVEN M. BECKER, JASON COPE
-
Publication number: 20080113368Abstract: A set of relationships using properties of the DNA molecule and its hydrogen bridge electron cycloid motion tied to the Fibonacci-Lucas series concepts and a complex number Argand diagram to provide a computer-implemented set of numbers to describe the number of DNA molecular bases traveling away from a starting point, the number of DNA molecular divisions away from the starting point molecule, and the triplet letter selection occurring at the new location.Type: ApplicationFiled: December 27, 2007Publication date: May 15, 2008Inventor: Harry MONTAGUE
-
Publication number: 20080113369Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for DGAT2.Type: ApplicationFiled: October 29, 2007Publication date: May 15, 2008Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20080113370Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.Type: ApplicationFiled: October 29, 2007Publication date: May 15, 2008Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20080113371Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for BACE.Type: ApplicationFiled: October 29, 2007Publication date: May 15, 2008Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20080113372Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for GCGR.Type: ApplicationFiled: October 29, 2007Publication date: May 15, 2008Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20080113373Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APP.Type: ApplicationFiled: October 29, 2007Publication date: May 15, 2008Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20080113374Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for FBP1.Type: ApplicationFiled: October 29, 2007Publication date: May 15, 2008Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20080113375Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for SOD1.Type: ApplicationFiled: October 29, 2007Publication date: May 15, 2008Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20080113376Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MYD1.Type: ApplicationFiled: October 30, 2007Publication date: May 15, 2008Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20080113377Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for proto-oncogene MET.Type: ApplicationFiled: October 30, 2007Publication date: May 15, 2008Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20080113378Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for IRAK4.Type: ApplicationFiled: October 30, 2007Publication date: May 15, 2008Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe